March 21, 2023 7:21am

Volatility reigns after banking backlash infects cell and gene sector following March’s sessions of 4 positive and 10 negative closes

Volatility is also a measure of price and can be calculated by using many methods but three types +historical, implied and future-realized … unpredictability.  

Pre-open Indications: 1 Sell into Strength, 1 Positive and 2 Negative Indications

A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined, evaluated and reported.

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  Join me … in the NO spin zone.

The 8:00 a.m. edition


Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session. My interpretation of the morning’s numbers is written to be informative; it’s built on will happen behind the headlines today, not tomorrow or yesterday …

 

Dow futures are UP +0.76% or (+248 points), S&P futures are UP +0.60% or (+24 point) and NASDAQ futures are UP +0.29% or (+36 points) early in the pre-open – so far

Stock futures are on the rise on Tuesday,

European markets were higher,

Asia-Pacific markets also rose.

 

Henry’omics:

We need to understand the macro to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes Stocks rose Monday, as investors grew hopeful that a crisis in the banking sector may be easing. The Dow closed UP +382.60 points (+1.20%), the S&P closed UP +34.93 points (+0.89%) while the Nasdaq closed UP +45.03 points (+0.39%).

The Fed's two-day meeting kicks off Tuesday, and the central bank may have a hard time hiking its key interest rate on Wednesday.

Economic Data Docket: home sales data

 

Friday’s (3/20) … RegMed Investors’ (RMi) closing bell: “cell and gene therapy equities are back in the trenches with share pricing hunkering down. After a week of “idiot management” and more “bad actions” are coming out at Silicon Valley Bank (SVB) that endangered the sector as a whole that will be slow to come back.” … https://www.regmedinvestors.com/articles/12880

RegMed Investors (RMi) Research Note: Q4 and FY22 earnings reporting … “The cell and gene therapy sector fluctuates in revenues, collaboration, regulatory submissions and expenses, but the changes may alarm investors who prefer to see expectation and consensus stability and share pricing growth” https://www.regmedinvestors.com/articles/12843 --- 26 of 35 (my coverage group)

 

Ebb and flow:

Q1/23 –

March – 4 positive and 10 negative closes

·         February – 1 holiday, 2 vacation, 7 negative and 8 positive closes

·         January – 2 holidays, 11 positive and 9 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Negative indications:

Monday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)

·         Compass Therapeutics (CMPX) closed down -$0.19 after Friday’s -$0.02 with a negative -$0.16 or -4.98% aftermarket indication

·         AxoGen (AXGN) closed up +$0.26 with a negative -$0.06 or -0.71% aftermarket indication.

Sell into Strength:

Monday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)

·         Sage Therapeutics (SAGE) closed up +$1.23 with a positive +$0.67 or +1.52% aftermarket indication

Positive Indications:

Monday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)

·         Verve Therapeutics (VERV) closed down -$0.13 with a positive +$0.65 or +3.98% aftermarket indication.

 

The BOTTOM LINE: I try to keep it simple and short!

It’s time for some upward momentum …

Also, the rush of Q4 and FY22 earnings to release is STILL on … I do NOT believe there are not a lot of cell/gene therapy companies in position yet – UNTIL earnings (Q4 and FY22) are reported – any breakout is a false hope with the inevitable downside re-occurring.

·         26 of my 35 covered have reported - 9 remaining

·         There are more coming – waiting for announcements

I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product.

And I can always be WRONG but, I am mostly EARLY!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.